Authors
Loading...
Experimental evidence demonstrates SATB2's role in epigenetic reprogramming and therapy resistance in Ph+ B-ALL.
Benjamin Mizukawa (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: